NASDAQ:ATRS - Nasdaq - US0366421065 - Common Stock
We assign a fundamental rating of 3 out of 10 to ATRS. ATRS was compared to 194 industry peers in the Pharmaceuticals industry. ATRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATRS is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Altman-Z | 8.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.59
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 | ||
P/S | 5.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.43 | ||
P/tB | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 | ||
Altman-Z | 8.15 |